Jason Aryeh insider trades: Ligand Pharmaceuticals (LGND) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
and 7 more companies
Open-market buys and sales
101 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | LGND | ↓ Sell | 282 | $319.99 | $90K | Direct | Nov 6, 2026 (2d) |
| Nov 2, 2026 | LGND | ↓ Sell | 2,111 | $320.30 | $676K | Direct | Nov 3, 2026 (1d) |
| Jun 11, 2026 | LGND | ↓ Sell | 5,000 | $250.00 | $1.3M | Direct | Jun 12, 2026 (1d) |
| May 18, 2026 | OBIO | ↑ Buy | 665 | $3.75 | $2K | Direct | May 20, 2026 (2d) |
| May 15, 2026 | OBIO | ↑ Buy | 8,971 | $3.90 | $35K | Direct | May 19, 2026 (4d) |
| Sep 23, 2025 | LGND | ↓ Sell | 10,000 | $170.81 | $1.7M | Direct | Sep 24, 2025 (1d) |
| Sep 19, 2025 | OBIO | ↑ Buy | 1,000 | $2.45 | $2K | Direct | Sep 19, 2025 (0d) |
| Sep 3, 2019 | LGND | ↑ Buy10b5-1 | 750 | $87.01 | $65K | Direct | Sep 4, 2019 (1d) |
| Aug 5, 2019 | LGND | ↑ Buy10b5-1 | 746 | $90.01 | $67K | Direct | Aug 6, 2019 (1d) |
| Jul 31, 2019 | LGND | ↑ Buy10b5-1 | 4,004 | $99.22 | $397K | Direct | Jul 31, 2019 (0d) |
| Jul 16, 2019 | MACK | ↑ Buy | 302 | $5.44 | $2K | Direct | Jul 18, 2019 (2d) |
| Jul 12, 2019 | MACK | ↑ Buy | 3,500 | $5.68 | $20K | Direct | Jul 15, 2019 (3d) |
| Jun 11, 2019 | LGND | ↑ Buy10b5-1 | 250 | $107.01 | $27K | Direct | Jun 12, 2019 (1d) |
| May 31, 2019 | LGND | ↑ Buy10b5-1 | 1,000 | $109.51 | $110K | Direct | May 31, 2019 (0d) |
| May 20, 2019 | LGND | ↑ Buy10b5-1 | 250 | $112.01 | $28K | Direct | May 22, 2019 (2d) |
| May 14, 2019 | LGND | ↑ Buy10b5-1 | 250 | $112.51 | $28K | Direct | May 16, 2019 (2d) |
| Mar 13, 2019 | LGND | ↑ Buy | 202 | $112.51 | $23K | Indirect | Mar 15, 2019 (2d) |
| Aug 17, 2018 | LGND | ↓ Sell | 27,942 | $241.94 | $6.8M | Indirect | Aug 17, 2018 (0d) |
| Mar 9, 2018 | LGND | ↓ Sell | 7,500 | $175.73 | $1.3M | Indirect | Mar 9, 2018 (0d) |
| Feb 23, 2018 | LGND | ↓ Sell | 3,417 | $155.00 | $530K | Indirect | Feb 27, 2018 (4d) |
| Nov 17, 2017 | LGND | ↓ Sell | 24,400 | $140.22 | $3.4M | Indirect | Nov 20, 2017 (3d) |
| Aug 23, 2017 | LGND | ↓ Sell | 2,000 | $127.99 | $256K | Indirect | Aug 25, 2017 (2d) |
| May 23, 2017 | ARLZ | ↓ Sell | 388,685 | $1.44 | $559K | By JALAA Equities, LP | May 24, 2017 (1d) |
| May 15, 2017 | NVLN | ↑ Buy | 361 | $8.95 | $3K | Direct | May 17, 2017 (2d) |
| May 12, 2017 | LGND | ↓ Sell | 37,247 | $110.76 | $4.1M | Indirect | May 12, 2017 (0d) |
| Feb 28, 2017 | LGND | ↓ Sell | 32,000 | $106.35 | $3.4M | Indirect | Feb 28, 2017 (0d) |
| Nov 25, 2016 | LGND | ↓ Sell | 18,479 | $107.31 | $2.0M | Indirect | Nov 25, 2016 (0d) |
| Nov 18, 2016 | LGND | ↓ Sell | 6,330 | $105.28 | $666K | Indirect | Nov 18, 2016 (0d) |
| Sep 16, 2016 | ARLZ | ↑ Buy | 295,929 | $5.86 | $1.7M | By JALAA Equities, LP | Apr 25, 2017 (221d) |
| May 6, 2016 | LGND | ↓ Sell | 25,000 | $119.20 | $3.0M | Indirect | May 9, 2016 (3d) |
| Mar 8, 2016 | LGND | ↓ Sell | 6,129 | $101.18 | $620K | Indirect | Mar 9, 2016 (1d) |
| Dec 29, 2015 | QLTI | ↑ Buy | 18,400 | $2.50 | $46K | By JALAA Equities, LP | Dec 30, 2015 (1d) |
| Nov 11, 2015 | LGND | ↓ Sell | 3,000 | $101.49 | $304K | Indirect | Nov 13, 2015 (2d) |
| Jun 16, 2015 | QLTI | ↑ Buy | 288,000 | $3.47 | $999K | By JALAA Equities, LP | Jun 18, 2015 (2d) |
| Jun 4, 2015 | LGND | ↓ Sell | 1,640 | $92.68 | $152K | Indirect | Jun 8, 2015 (4d) |
| May 20, 2015 | LGND | ↓ Sell | 9,240 | $87.34 | $807K | Indirect | May 20, 2015 (0d) |
| Oct 9, 2014 | LGND | ↑ Buy | 11,000 | $42.99 | $473K | Indirect | Oct 9, 2014 (0d) |
| Feb 14, 2014 | LGND | ↓ Sell | 40,320 | $76.44 | $3.1M | Indirect | Feb 14, 2014 (0d) |
| Jun 18, 2012 | MYRX | ↑ Buy | 3,000 | $2.29 | $7K | By JALAA Equities, LP | Jun 20, 2012 (2d) |
| Jun 15, 2012 | MYRX | ↑ Buy | 5,025 | $2.36 | $12K | By JALAA Equities, LP | Jun 18, 2012 (3d) |
| Jun 7, 2012 | MYRX | ↑ Buy | 1,116 | $2.40 | $3K | By JALAA Equities, LP | Jun 11, 2012 (4d) |
| Jun 1, 2012 | LGND | ↑ Buy | 700 | $11.98 | $8K | Indirect | Jun 5, 2012 (4d) |
| May 31, 2012 | MYRX | ↑ Buy | 14,153 | $2.38 | $34K | By JALAA Equities, LP | Jun 1, 2012 (1d) |
| May 25, 2012 | MYRX | ↑ Buy | 1,153 | $2.47 | $3K | By JALAA Equities, LP | May 25, 2012 (0d) |
| May 22, 2012 | MYRX | ↑ Buy | 12,262 | $2.50 | $31K | By JALAA Equities, LP | May 23, 2012 (1d) |
| May 18, 2012 | MYRX | ↑ Buy | 11,000 | $2.60 | $29K | By JALAA Equities, LP | May 21, 2012 (3d) |
| Dec 5, 2011 | MYRX | ↑ Buy | 30,792 | $2.75 | $85K | By JALAA Equities, LP | Dec 6, 2011 (1d) |
| Dec 2, 2011 | MYRX | ↑ Buy | 70,218 | $2.67 | $187K | By JALAA Equities, LP | Dec 5, 2011 (3d) |
| Nov 30, 2011 | MYRX | ↑ Buy | 9,900 | $2.60 | $26K | By Trust | Dec 1, 2011 (1d) |
| Nov 29, 2011 | MYRX | ↑ Buy | 91,800 | $2.58 | $237K | By JALAA Equities, LP | Dec 1, 2011 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LGND insiders
Open-market trades in the last 12 months
About Jason Aryeh's insider trades
Jason Aryeh is a director at Ligand Pharmaceuticals (LGND). Since May 30, 2007, Jason has reported 49 open-market purchases worth $5.5M and 52 sales worth $40.5M on SEC Form 4. In the last 12 months: 2 buys ($37K) and 3 sales ($2.0M).
Their filings also include grants and awards (49 filings), option exercises (18 filings), other transactions (8 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.